CD22 CAR-T细胞在儿童和成人B-ALL中显示高缓解率和安全性:1b期结果
该1b期平行临床试验使用闭环自动化制备的人源化CD22 CAR-T(含41BB共刺激域)治疗儿童和成人复发/难治B-ALL。19例入组,18例成功制备,16例输注;12/16(75%)达完全缓解,总体微小残留病阴性完全缓解率56%,中位缓解持续时间77天,复发时4/12(33%)可测样本CD22表达下调。
要点
- 16例输注患者中12例(75%)达完全缓解,总体微小残留病阴性完全缓解率56%。
- 3-4级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征各仅1例,3例发生免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征。
- 中位缓解持续时间77天,复发时4/12(33%)可测样本CD22表达下调。
核心结论
- 儿童和成人复发/难治B-ALL中,CD22 CAR-T闭环自动化制备可行,与良好安全性特征和高完全缓解率相关。
研究设计与样本
- 平行1b期临床试验,采用现场自动化闭环制备人源化CD22 CAR-T(含41BB共刺激域),治疗儿童和成人重度经治复发/难治B-ALL。
- 19例患者入组,18例成功制备CD22 CAR-T,16例完成输注。
主要发现
- 16例输注患者中12例(75%)达完全缓解,总体微小残留病阴性完全缓解率为56%。
- 3-4级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征各仅1例发生。
- 3例患者发生免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征。
- 总体缓解持续时间有限,中位77天。
- 复发时4/12(33%)可测样本显示CD22表达下调。
局限性
- 总体缓解持续时间有限,中位77天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22+ malignancies with progression after CD19-directed therapies. Using on-site, automated, closed-loop manufacturing, we conducted parallel Phase 1b clinical trials investigating a humanized CD22-CAR with 41BB costimulatory domain in children and adults with heavily treated, relapsed/refractory (r/r) B-ALL. Of 19 patients enrolled, 18 had successful CD22-CAR manufacturing, and 16 patients were infused. High grade (3-4) cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS) each occurred in only one patient; however, three patients experienced immune-effector-cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Twelve of 16 patients (75%) achieved CR with an overall 56% MRD-negative CR rate. Duration of response was overall limited (median 77 days), and CD22 expression was downregulated in 4/12 (33%) available samples at relapse. In summary, we demonstrate that closed-loop manufacturing of CD22-CAR T cells is feasible and is associated with a favorable safety profile and high CR rates in pediatric and adult r/r B-ALL, a cohort with limited CD22-CAR reporting.
引用
- Schultz LM, Jeyakumar N, Kramer AM, et al. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia. 2024. PMID: 38491306. doi:10.1038/s41375-024-02220-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。